AB Science Corrects Adverse Event Data for Study AB09004
AB Science has issued a corrective press release regarding adverse event information from its AB09004 study. The update clarifies previously reported data.
AB Science has released a corrective press release concerning adverse events information from its Phase 2b/3 study, AB09004. This study evaluates masitinib in patients with chronic myeloid leukemia (CML).
The company states that inaccuracies were present in the initial reporting of the frequency of certain adverse events. AB Science has revised and corrected this data to ensure the accuracy and transparency of its reporting.
AB Science emphasized that these corrections to adverse event data do not alter the overall study findings or the assessment of masitinib's safety profile. The company continues to actively investigate masitinib's safety and efficacy across various indications.
AB Science is a biopharmaceutical company focused on the development of drugs for human and veterinary use. Their primary research compound is masitinib, which is being developed for multiple indications.